MRSH Marsh & McLennan Companies, Inc.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

MRSH's Archer service targets asset-intensive reinsurance, offering end-to-end support that could add recurring revenue and deepen client ties.

Marsh President and CEO John Doyle explains how businesses can treat resilience as a competitive advantage rather than a defensive strategy. Doyle explains the importance of scenario planning to navigate continuous disruption stemming from geopolitical volatility and complex supply chain dependencies.

Marsh President and CEO John Doyle says artificial intelligence is fundamentally changing the traditional career trajectory for young professionals. Speaking with The Wall Street Journal's Chip Cutter, Doyle explains how incoming "AI natives" will bypass years of entry-level data collection, allowing them to challenge legacy workflows and advance up the corporate pyramid at unprecedented speeds.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

MRSH will likely see long-term revenue support as asset owners favor cash, infrastructure and emerging markets while advisory demand expands.

Geopolitical risk in the Middle East has moved from background noise to headline driver, with Iran, the Strait of Hormuz and Houthi attacks all reshaping how capital views global shipping and war-related exposure. Investors now face a rare moment where insurance-linked stocks tied to these routes could see their risk, pricing power and demand profile change at the same time. This article walks through 3 stocks from our Global Marine Insurance and War-Risk Insurers screener that appear most...

Arthur J. Gallagher's acquisition of Innovise expands its commercial brokerage reach, adds surety expertise and creates cross-selling opportunities across specialized industries.

eHealth says surging 2027 health costs are pushing smaller employers toward ICHRAs, potentially expanding individual coverage demand.

Due to Marsh & McLennan’s underperformance relative to the S&P 500 Index over the past year, analysts are cautious about the stock’s prospects.

Doyle exercised options granted in 2017 through a pre-arranged Rule 10b5-1 trading plan, retaining ~117,000 shares worth $21.94 million after transaction.

MRSH is leaning on AI, data and technology to support growth and margins as softer insurance pricing puts pressure on premium-linked revenues.

MRSH's AI initiatives, consulting momentum and acquisitions support growth, but rising costs, debt and valuation risks temper the case for holding Marsh.

Here is how Healthcare Services (HCSG) and Marsh (MRSH) have performed compared to their sector so far this year.

Business services providers play a critical role for enterprises, assisting them with everything from new hardware integrations to consulting and marketing. Furthermore, the demand for their offerings is rising as more clients outsource non-core functions, a trend that has enabled the industry to return 19.8% over the past six months. At the same time, the S&P 500 was up 11.7%.

Rising employer healthcare costs could boost Marsh's consulting demand and create growth avenues for UnitedHealth and Centene through cost-control solutions.

Cyber Protect launch and Marsh Re rebrand set the scene for Marsh & McLennan Companies stock Marsh & McLennan Companies (MRSH) has drawn investor attention after two recent moves. The company launched Cyber Protect in Asia with Resilience and rolled out a group-wide rebrand that brings Guy Carpenter under the Marsh Re banner. Recent moves such as Cyber Protect and the Marsh Re rebrand come after a mixed period for Marsh & McLennan Companies. The share price is US$187.58 after a recent 7 day...

Marsh & McLennan Companies stock has posted a 28.4% gain over the past five years, yet current valuation checks send mixed signals as the intrinsic value estimate suggests upside while market multiples lean the other way. At the same time, the broader scorecard points to a middle ground rather than a clearly cheap or clearly expensive stock. A 28.4% return over five years indicates Marsh & McLennan Companies has rewarded patient shareholders, which can influence how much of the quality story...

MRSH sees moderate 2027 U.S. pay hikes as AI reshapes compensation planning and Cyber Protect expands its risk services across Asia.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Marsh (NYSE:MRSH) and the best and worst performers in the insurance brokers industry.

Marsh (MRSH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CLH's 16% six-month gain is backed by rising 2026 estimates, strong liquidity and ongoing buybacks, supporting EPS growth.

Meta's $14 Billion Data Center Project Hit by Major Insurance Concerns

Meta Platforms' (META) and BlackRock's (BLK) Sopaipilla data center campus in El Paso, Texas, is exp

While Marsh & McLennan has lagged the broader market over the past 52 weeks, Wall Street remains cautiously optimistic about its outlook.

Marsh & McLennan Companies (MRSH) is back in focus after its Marsh McLennan Agency unit agreed to acquire Accel Holdings, an Iowa based insurance and advisory firm, expanding its Midwest footprint and service mix. See our latest analysis for Marsh & McLennan Companies. For investors watching Marsh & McLennan Companies over the past year, momentum has recently improved, with a 30 day share price return of 7.26% and a 90 day share price return of 20.18%, although the 1 year total shareholder...

ARX's Q2 results may face pressure from weaker Underwriting and MGA profitability despite strong premium and investment income growth.

MRSH's MMA is set to acquire Accel, expanding its Midwest reach and adding agribusiness, benefits, wealth and retirement capabilities.

American International heads into Q2 earnings with premium growth expectations, but a sharp drop in net investment income could cloud results and keep an earnings beat uncertain.

Fidelity National tops Q2 EPS estimates as Banking Solutions fuels growth and margins improve, but the company lowers its full-year revenue and earnings outlook.

ALL's Q2 earnings may face pressure from weaker Property-Liability underwriting despite expected premium and investment income growth.

Here is how Healthcare Services (HCSG) and Marsh (MRSH) have performed compared to their sector so far this year.

MET heads into Q2 results with rising earnings estimates and expected strength in Group Benefits and Retirement & Income Solutions. Will it deliver a beat?

WU's Q2 earnings miss estimates as Consumer Money Transfer retail weakness and higher expenses hurt margins, even as digital and consumer services show growth.

EEFT misses Q2 earnings and revenue estimates as Cross-Border Payments weakens, while growth in Payments Infrastructure and epay, along with digital initiatives, helps offset some of the pressure.

SKWD heads into Q2 earnings with strong premium and investment income growth expected, while rising costs remain a key watchpoint.

Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark U.S. Concentrated Strategy”. A copy of the letter can be downloaded here. The strategy returned 9.21% (net) in the second quarter, lagging the Russell 1000 Value Index’s 13.87%. U.S. equities finished higher during the quarter, with nine of eleven GICS sectors posting gains, led […]

Marsh & McLennan Companies (MRSH) is in focus after reporting second quarter 2026 earnings, alongside an update on its ongoing share repurchase program and progress on automation initiatives with SS&C Blue Prism. See our latest analysis for Marsh & McLennan Companies. Marsh & McLennan Companies' latest earnings and buyback update come after a mixed share price run, with a 30 day share price return of 7.67% but a year to date share price return down 3.33%, while the 1 year total shareholder...

AON heads into Q2 earnings with Commercial Risk Solutions growth and a positive Earnings ESP, but can rising costs temper the upside?

CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls

Marsh (MRSH) reports a 6% revenue increase and a 9% rise in adjusted EPS, driven by strategic investments and robust consulting growth.

Financial stocks were higher in late Tuesday afternoon trading, with the NYSE Financial Index rising

Financial stocks advanced in Tuesday afternoon trading, with the NYSE Financial Index rising 0.8% an

MRSH beats Q2 earnings estimates as Consulting and Risk & Insurance Services fuel revenue growth despite higher operating expenses.

Marsh & McLennan Companies (NYSE:MRSH) reported higher second-quarter revenue and earnings, with management pointing to continued demand for its risk, insurance and consulting services despite pricing pressure in commercial insurance and reinsurance markets. John Doyle, President and CEO of Mar

While the top- and bottom-line numbers for Marsh (MRSH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Earnings beat expectations as shares edge higherMarsh & McLennan Companies (NYSE:MRSH) reported stronger-than-expected second-quarter results on Tuesday, exceeding Wall Street forecasts for both earnings and revenue as demand remained healthy across its core businesses. Shares rose 1.

Marsh (MRSH) delivered earnings and revenue surprises of +2.78% and +1.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Professional services firm Marsh (NYSE:MRSH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 6.2% year on year to $7.40 billion. Its non-GAAP profit of $2.96 per share was 2.3% above analysts’ consensus estimates.